0001140361-18-031327.txt : 20180703
0001140361-18-031327.hdr.sgml : 20180703
20180703185037
ACCESSION NUMBER: 0001140361-18-031327
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180702
FILED AS OF DATE: 20180703
DATE AS OF CHANGE: 20180703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCarthy Sean A.
CENTRAL INDEX KEY: 0001654058
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 18938988
MAIL ADDRESS:
STREET 1: 343 OYSTER POINT BLVD.
STREET 2: SUITE 100
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2018-07-02
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001654058
McCarthy Sean A.
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
2018-07-02
4
M
0
13052
1.5749
A
95115
D
Common Stock
2018-07-02
4
S
0
13052
23.4223
D
82063
D
Stock Option (Right to Buy)
1.5749
2018-07-02
4
M
0
13052
0.00
D
2025-02-08
Common Stock
13052
162174
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
Share numbers reflect the transfer of (i) 77,118 shares to the reporting person and (ii) 77,119 shares to the reporting person's ex-wife, from McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees, pursuant to a domestic relations order.
This transaction was executed in multiple trades in prices ranging from $22.56 to $23.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This option vests in 48 substantially equal monthly installments starting on the last day of January 2015.
/s/ Debanjan Ray, as Attorney-in-Fact for Sean A. McCarthy
2018-07-03